Medicines: register to manufacture, import or distribute active substances

AI Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) provides this guidance for UK-based organizations manufacturing, importing, or distributing active substances used in medicinal products. Under the UK regulatory framework, all such entities must register via the MHRA PCL Portal and strictly adhere to Good Manufacturing and Distribution Practice (GMDP) standards. While this document is general guidance rather than a report on a specific company, it establishes the mandatory protocols for maintaining legal operation. Key required actions include completing the initial registration, which typically takes 60 working days, and updating registrations when details change. Variations requiring no inspection are processed in 30 days. Organizations must also submit an annual compliance report by April 30 each year. If an inspection is deemed necessary, the MHRA will coordinate a site visit, which incurs additional fees. To avoid annual service charges when closing operations, termination requests must be submitted by December 31. Failure to comply with these registration and reporting standards or failing to meet GMDP requirements may result in regulatory action. This framework ensures the safety and quality of active ingredients within the UK supply chain.